Nitrazepam
As of the edition of 20 October 2026, Nitrazepam is a small molecule: marketed, first approved in 1965 (CH); acts on GABRA1, GABRB2 and GABRG2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1986
- Kind
- Small molecule
- Brand name
- Mogadon
- First approved
- 1 March 1965 (CH)
- Approvals on record
- 2 in 2 regions
- Holder of the most recent approval
- VIATRIS MEDICAL; 2 holders in all
- Registered trials
- 2, 1 stopped early
- Disease areas
- Mental health; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 1 | 1 | 0 | 0 |
| Phase 3 | 1 | 0 | 0 | 1 |
| All trials | 2 |